Ublituximab - TG Therapeutics
Alternative Names: BRIUMVI; EMAB-6; EMAB-603; LFB-R603; R603; Rituximab biobetter - TG Therapeutics; TG-1101; TG-20; TGTX-1101; Ublituximab-xiiy - TG Therapeutics; Utuxin™Latest Information Update: 23 Oct 2026
At a glance
- Originator LFB Biotechnologies; rEVO Biologics
- Developer Johns Hopkins University; LFB Biotechnologies; Neuraxpharm; TG Therapeutics Inc
- Class Antineoplastics; Antipsychotics; Biobetters; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Yes - Neuromyelitis optica; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Marginal zone B-cell lymphoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Multiple sclerosis
- Phase II Myasthenia gravis; Schizophrenia
- Preregistration Submission Withdrawal Chronic lymphocytic leukaemia
- Discontinued Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Neuromyelitis optica; Non-Hodgkin's lymphoma; Richter's syndrome
Most Recent Events
- 21 Oct 2026 Updated efficacy data from a phase II trial in Multiple sclerosis released by TG Therapeutics
- 24 Jul 2026 Phase-II/III clinical trials in Multiple sclerosis (In children, In adolescents) in Poland (IV)(NCT07220252)
- 06 Jul 2026 Phase-II clinical trials in Schizophrenia (Treatment-resistant) in USA (IV) (NCT07680946)